EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Status:
Completed
Trial end date:
2020-10-09
Target enrollment:
Participant gender:
Summary
This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to
directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin
(DAPA), EQW plus DAPA, combined DAPA/metformin extended release (XR) and the weight loss
medication, phentermine/topiramate extended release (PHEN/TPM ER) on metabolic and
endocrinological parameters in overweight/obese non-diabetic women with PCOS. In this study,
we will examine the efficacy of these therapies on metabolic parameters, body weight and body
composition, anthropometric measurements, and reproductive function in a well-defined group
of pre-menopausal overweight/obese, non-diabetic women with PCOS, focusing on their
relationship to insulin resistance and obesity. We hope to determine which treatment(s)
addressing the multifaceted disturbances of individual subgroups emerge as the preferable
therapy.